Literature DB >> 29405329

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

Norah A Terrault1, Anna S F Lok2, Brian J McMahon3, Kyong-Mi Chang4, Jessica P Hwang5, Maureen M Jonas6, Robert S Brown7, Natalie H Bzowej8, John B Wong9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29405329      PMCID： PMC5975958          DOI： 10.1002/hep.29800

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  257 in total

Review 1.  Management of hepatitis B: 2000--summary of a workshop.

Authors:  A S Lok; E J Heathcote; J H Hoofnagle
Journal:  Gastroenterology       Date:  2001-06       Impact factor: 22.682

2.  Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection.

Authors:  M S Sulkowski; D L Thomas; R E Chaisson; R D Moore
Journal:  JAMA       Date:  2000-01-05       Impact factor: 56.272

3.  Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.

Authors:  M den Brinker; F W Wit; P M Wertheim-van Dillen; S Jurriaans; J Weel; R van Leeuwen; N G Pakker; P Reiss; S A Danner; G J Weverling; J M Lange
Journal:  AIDS       Date:  2000-12-22       Impact factor: 4.177

4.  Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens.

Authors:  J Hoff; F Bani-Sadr; M Gassin; F Raffi
Journal:  Clin Infect Dis       Date:  2001-03-07       Impact factor: 9.079

5.  Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation.

Authors:  F Y Yao; R W Osorio; J P Roberts; F F Poordad; M N Briceno; R Garcia-Kennedy; R R Gish
Journal:  Liver Transpl Surg       Date:  1999-11

6.  Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.

Authors:  Y Benhamou; M Bochet; V Thibault; V Di Martino; E Caumes; F Bricaire; P Opolon; C Katlama; T Poynard
Journal:  Hepatology       Date:  1999-11       Impact factor: 17.425

7.  Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors.

Authors:  W Yeo; P K Chan; S Zhong; W M Ho; J L Steinberg; J S Tam; P Hui; N W Leung; B Zee; P J Johnson
Journal:  J Med Virol       Date:  2000-11       Impact factor: 2.327

8.  Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy.

Authors:  C Manegold; C Hannoun; A Wywiol; M Dietrich; S Polywka; C B Chiwakata; S Günther
Journal:  Clin Infect Dis       Date:  2000-12-13       Impact factor: 9.079

9.  Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study.

Authors:  Maurizia Rossana Brunetto; Filippo Oliveri; Barbara Coco; Gioacchino Leandro; Piero Colombatto; Juliana Monti Gorin; Ferruccio Bonino
Journal:  J Hepatol       Date:  2002-02       Impact factor: 25.083

10.  Risk of hepatitis B transmission after amniocentesis in chronic hepatitis B carriers.

Authors:  J M Alexander; R Ramus; G Jackson; B Sercely; G D Wendel
Journal:  Infect Dis Obstet Gynecol       Date:  1999
View more
  630 in total

1.  Nonalcoholic fatty liver disease is associated with lower hepatitis B viral load and antiviral response in pediatric population.

Authors:  Lu Wang; Yijin Wang; Shuhong Liu; Xiangwei Zhai; Guangde Zhou; Fengmin Lu; Jingmin Zhao
Journal:  J Gastroenterol       Date:  2019-05-27       Impact factor: 7.527

2.  A hepatitis B virus causes chronic infections in equids worldwide.

Authors:  Andrea Rasche; Felix Lehmann; Nora Goldmann; Michael Nagel; Andres Moreira-Soto; Daniel Nobach; Ianei de Oliveira Carneiro; Nikolaus Osterrieder; Alex D Greenwood; Eike Steinmann; Alexander N Lukashev; Gerhard Schuler; Dieter Glebe; Jan Felix Drexler
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-30       Impact factor: 11.205

Review 3.  HBV/HDV Coinfection: A Challenge for Therapeutics.

Authors:  Christopher Koh; Ben L Da; Jeffrey S Glenn
Journal:  Clin Liver Dis       Date:  2019-05-24       Impact factor: 6.126

Review 4.  Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift.

Authors:  Yun-Fan Liaw
Journal:  Hepatol Int       Date:  2019-09-26       Impact factor: 6.047

Review 5.  Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV.

Authors:  Robert C Bollinger; Chloe L Thio; Mark S Sulkowski; Jane McKenzie-White; David L Thomas; Charles Flexner
Journal:  Lancet HIV       Date:  2019-12-20       Impact factor: 12.767

6.  Blood-borne viral infections in pediatric hemodialysis.

Authors:  Shina Menon; Raj Munshi
Journal:  Pediatr Nephrol       Date:  2018-07-21       Impact factor: 3.714

7.  APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients.

Authors:  Jia-Horng Kao; Tung-Hung Su; Wen-Juei Jeng; Qin Ning; Tai-Chung Tseng; Yoshiyuki Ueno; Man-Fung Yuen
Journal:  Hepatol Int       Date:  2021-07-23       Impact factor: 6.047

8.  Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus.

Authors:  Tim R Cressey; Linda Harrison; Jullapong Achalapong; Prateep Kanjanavikai; Orada Patamasingh Na Ayudhaya; Prateung Liampongsabuddhi; Thitiporn Siriwachirachai; Chaiwat Putiyanun; Pornnapa Suriyachai; Camlin Tierney; Nicolas Salvadori; Dujrudee Chinwong; Luc Decker; Yardpiroon Tawon; Trudy V Murphy; Nicole Ngo-Giang-Huong; George K Siberry; Gonzague Jourdain
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

Review 9.  The evolution and clinical impact of hepatitis B virus genome diversity.

Authors:  Peter A Revill; Thomas Tu; Hans J Netter; Lilly K W Yuen; Stephen A Locarnini; Margaret Littlejohn
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-05-28       Impact factor: 46.802

10.  Antiviral Properties and Mechanism of Action Studies of the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379.

Authors:  Jan Martin Berke; Pascale Dehertogh; Karen Vergauwen; Wendy Mostmans; Koen Vandyck; Pierre Raboisson; Frederik Pauwels
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.